Loading
Life sciences · Journal article
Medcomm · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) is associated with adverse liver and non‐liver outcomes, but the impact of coexisting sarcopenia‐related abnormalities (e.g., low muscle strength [MS], muscle mass, and physical performance) remains unclear. In a prospective UK Biobank cohort ( n = 438,748), we evaluated their joint associations with incidence and risks of all‐cause mortality, cirrhosis, hepatocellular carcinoma (HCC), cardiovascular disease (CVD), chronic kidney disease (CKD), non‐liver cancers, and obesity‐related cancers across MASLD and sarcopenia‐related abnormality status. Over a median follow‐up of 13.8 years, 401 HCC, 1714 cirrhosis, 39,534 CVD, 19,637 CKD, 38,240 non‐liver cancers, 12,536 obesity‐related cancers, and 34,801 deaths occurred. A stepwise increase in both incidence and adjusted risk of liver and non‐liver outcomes was observed across MASLD and sarcopenia strata. Within the coexistence group, the obesity (vs. non‐obesity) subgroup generally had higher risks. For example, for cirrhosis, adjusted hazard ratios increased from 3.93 to 7.36 then 8.48 with MASLD alone, coexisting MASLD with low MS overall and coexisting MASLD, low MS and obesity, respectively. Similar findings were observed in external validation analyses using the 2011–2018 US National Health and Nutrition Examination Survey cohort. Together, these observations inform risk stratification strategy and management of MASLD to include sarcopenia assessment.